Please note that any links referenced in this recording can be found in the Prostate Cancer Forum. Log in top right.
We also welcome our Advisory Board Member, Allen Edel (@TallAllen) tonight to contribute his moderation.
Topics:
No CT or bone scans prior to Gleason 9 surgery; peritoneal implants; accessing darolutamide; tragic consequences of complementary medicine alone; positive darolutamide experience; treating advanced PCa without hormone therapy; Tru-beam for spot radiation; oligometastasis radiation; pros and cons of debulking the primary tumor; treatment after enzalutamide fails.
Kudos to Peter Kafka, our Board Chair, and our partner, Pacific Cancer Foundation , featured in this week-end’s article about AnCan! Enough from me – the article says it all!
Our wonderful webdesigner/master and Advisory Board member, Jackie Zimmerman, recently revived her own blog. In her most recent entry, Jackie makes some pertinent observations about life as a patient advocate ….. worth a read! Btw, for those of us older than a certain age, ‘OG’ means ‘original’.
Repeat PSMA scans; Dr. Oh at Mount Sinai; Radiation and inflammation; using a physiatrist; medical marijuana dosage, interactions and side effects; UsTOO Chicago Meeting recording https://ustoo.org/PathwaysChicago2019 ; intermediate vs continuous hormone therapy; Testosterone recovery on IHT; AR V7 responses from Dr. Antonarakis; urinary frequency and drug discussion; sleeping pills; SBRT for spot radiation; bad side effects from apalutamide; distinguishing adjuvant hormone treatment from metastatic HT treatment; LHRH + abiraterone adjuvant hormone therapy
Listen to Jake Hannam outline the groups we run at AnCan.
And visit our YouTube Channel, if you want to listen to any recorded groups ….. for prostate cancer, MS, or sarcoidosis as well as excellent webinars on various topics like diet, exercise and genome sequencing.
Whilst trying to clear my e-mail backlog before year-end, I came across this article from NYU Langone Health Center with the self-explanatory title, “Breast Cancer Screening Found Effective in Men at High Risk for the Disease.”.
In deference to MBCC and our male breast cancer group, that is currently on holiday hiatus and restarts in January, I am posting it. Men with pertinent risk factors like a BRCA mutation, family history, or Ashkenazi ancestry should take particular note.
Advisory Board member, Allen Edel authors an exceptional blog, Prostate Cancer News, Reviews & Views on various ‘technical’ prostate cancer matters – that’s just one of the reasons we are proud to have him on our Advisory Board. You’ll find the blog here where you can sign up for new posts … as of course you can with AnCan just to the right!
Allen’s latest post is an excellent treatise on PSMA, based on reviewing several studies. He makes a number of interesting points to bear in mind when considering PSMA based protocols, amongst them:
consider getting both a PSMA and FDG basedPET/ CT scan before opting for radionuclide treatment
PSMA is very heterogeneous i.e. it can be expressed differently certainly within the same man and maybe even amongst cells in the same tumor
PARP-I’s can promote the potency of PSMA based treatments
Once again, AnCan expresses deep gratitude to Allen for keeping us well informed on important aspects of treatment that many medical practitioners, never mind advocates and patients, would otherwise miss.
Chris O’Connor lost; access to pain meds; benefits of darolutamide; NIH – Bone biopsy experience, mutation analysis & CTC’s; CBD – hemp or marijuana?; failing Xytiga – AR V7?; darlutamide and AR V7; exercise and chemotherapy; lung nodules
On all too rare occasion, we love to share some joy! Jerry Pelfrey recently wrote AnCan to share a pix from a Thanksgiving family reunion. On behalf of himself and his wife Debbie, who has attended our advanced cancer caregiver sessions, he writes:
During our family Thanksgiving we had pictures taken of the family. Debbie surprised us by having blue flowers and ribbons for each of us to represent Prostate cancer. Each member said it would go on their work desk or they would wear it. So, I thought you might like to see the picture.
Although he lives a couple of hours north, Jerry is currently in the midst of proton-beam radiation at Mayo Clinic in Phoenix for his advanced prostate cancer. Thanks to Ken Anderson, our Board Member and a long-time realtor in the Phoenix Metro market, AnCan has assisted the Pelfreys in locating affordable accommodation much closer to the facility. Jerry – we wish you & Debbie well and all the family a happy Holiday Season.
A report from MedPage Today last week suggests there is no role for denosumab (Xgeva or Prolia) in early stage, high risk breast cancer that is bone mets free. Read the article here.
There are many similarities between breast and prostate cancer in their respective disease patterns. Our PCa groups often discuss the timing of bone strengthener use. A quick review of the literature reveals one meta-study that supports the use of denosumab.; however it does not analyse the results by disease stage of those studied.
This is of personal interest to the Author’s experience. I was placed on bone support treatment at the outset of 28 months hormone deprivation therapy because my bone density was borderline osteoporitic, albeit no observed bone mets – and it helped me over the course of my treatment. Since baseline bone density at start of treatment is a relevant factor, why was that not factored into the equation?
